Above the specified price limit, Hong Kong public offering received 3165.1 times oversubscription.
HaiXi New Medicine (02637) announced the results of its allocation, with the company selling 11.5 million H shares globally, of which the Hong Kong public offering accounted for...
(02637) announces the distribution results. The company globally issued 11.5 million H-shares, with 10% allocated for public sale in Hong Kong and 90% for international sale. The final offering price was HK$86.40 per share, with a net fundraising of approximately HK$940 million through the global sale. Each trading unit consists of 50 H-shares, and it is expected that trading of H-shares will commence at 9:00 am on Monday, October 20, 2025, on the Hong Kong Stock Exchange.
The public sale in Hong Kong was oversubscribed by 3165.1 times, while the international sale was oversubscribed by 6.3 times.
Related Articles

Through the hearing of the Hong Kong Stock Exchange, Pony.ai (PONY.US) accelerates cross-border capital globalization in the United States and Hong Kong.

Boeing Company (BA.US) has received approval from the FAA to increase the monthly production limit of 737 MAX aircraft to 42.

MRAM, sponsored by Taiwan Semiconductor Manufacturing Co., Ltd. ADR(TSM.US), makes a significant breakthrough.
Through the hearing of the Hong Kong Stock Exchange, Pony.ai (PONY.US) accelerates cross-border capital globalization in the United States and Hong Kong.

Boeing Company (BA.US) has received approval from the FAA to increase the monthly production limit of 737 MAX aircraft to 42.

MRAM, sponsored by Taiwan Semiconductor Manufacturing Co., Ltd. ADR(TSM.US), makes a significant breakthrough.

RECOMMEND